Cardiff Oncology, Nerviano amend 2017 exclusive license agreement
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
12:33:05 PM UTC
SquawkNews
Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. NASDAQ:CRDF ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.